The SeroSelectTB test will be evaluated at 57 primary healthcare units in six Woredas of the West Gojjam Zone of the Amhara Region, Ethiopia. TB suspects self-reporting to the study sites will be randomised in two arms: standard-of-care or SeroSelectTB. In Ethiopia, 3198 TB suspects will be enrolled in each study arm.

 

This section will be updated as the clinical trial proceeds.